Later-Line Therapies Drive Biosimilar Prescriptions in Turkish Rheumatology Practices

October 15, 2025

Researchers report that biosimilar use was not influenced by disease type but correlated with treatment sequence, shorter disease duration, and female sex.

Biosimilar Bevacizumab Matches Avastin in Treating Retinopathy of Prematurity

October 14, 2025

FDA Approves Celltrion Aflibercept Biosimilar: Eydenzelt

October 13, 2025

Real-World Stability Confirmed for Biosimilar Ximluci in Prefilled Syringes

October 09, 2025

Review Identifies Gaps in Evidence on Biosimilar DMARD Use During Pregnancy

October 09, 2025

Biosimilars Help Alvotech Revenues Soar Over 400% Year Over Year

March 31st 2025

By Skylar Jeremias

Article

Alvotech's 427% revenue surge in 2024—fueled by its biosimilar portfolio and global expansion—highlights the booming profitability of biosimilars despite financial hurdles.

PBM Evolution Toward Value-Based Care Shifts to Transparent Pharmacy Pricing

March 30th 2025

By Cameron Santoro

Article

Josh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health, predict pharmacy benefit managers (PBMs) will evolve toward value-based care, mirroring the broader shift toward open-cost structures.

The Top 5 Biosimilar Articles for the Week of March 24

March 28th 2025

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of March 24, 2025.

FDA Approves Another Pair of Denosumab Biosimilars, Conexxence and Bomyntra

March 27th 2025

By Cameron Santoro

Article

The FDA approved another set of denosumab biosimilars, Conexxence/Bomyntra (denosumab-bnht), expanding treatment options for osteoporosis, bone metastases, and other bone-related conditions, amidst a flurry of similar approvals and legal settlements.

As Biosimilar Substitutions Become More Common, Education and Patient Counseling Are Paramount

March 27th 2025

By Luke Halpern

Article

Pharmacists play an essential role in counseling patients on biosimilar substitution protocols and following state regulations regarding interchangeable medications.

Adalimumab Biosimilars Show Similar Outcomes in Psoriasis After Nonmedical Switch

March 26th 2025

By Skylar Jeremias

Article

Switching between adalimumab products does not affect drug effectiveness or treatment duration in patients who have psoriasis, according to a Danish study.

Biosimilar Natalizumab-sztn Shows Comparable Efficacy and Safety to Tysabri in RRMS

March 25th 2025

By Cameron Santoro

Article

Biosimilar natalizumab demonstrated comparable efficacy, safety, and immunogenicity to reference drug Tysabri in patients with relapsing-remitting multiple sclerosis (RRMS), supporting its potential as a cost-effective treatment option.

BioRationality: How Developers Can Expand Their Monoclonal Antibody Biosimilar Portfolio

March 24th 2025

By Sarfaraz K. Niazi, PhD

Article

Monoclonal antibodies lead biosimilar approvals because of their large market size, well-defined regulatory pathways, and technological feasibility, whereas other biologics encounter development challenges but may see increased adoption as regulatory frameworks advance.

Patients With IBD Maintain Therapy 2 Years Post Switching to Infliximab Biosimilar

March 23rd 2025

By Deana Ferreri, PhD

Article

People with inflammatory bowel disease (IBD) who switched to the infliximab biosimilar CT-P13 had higher treatment persistence (84% and 91%) than those new to infliximab (66% and 53%), with no new safety concerns.

The Top 5 Biosimilar Articles for the Week of March 17

March 21st 2025

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of March 17, 2025.